Good morning, it's Paul & Jack here with the SCVR for Thursday.

Agenda

Paul's Section:

Pci- Pal (LON:PCIP) - strong progress in H1, but patent infringement allegations hang over the company, so risky until that's resolved.

Essensys (LON:ESYS) - share price has crashed this week, on disappointing growth. This software company is engaged in a risky strategy with high cash burn, but so far growth has disappointed.

Kitwave (LON:KITW) - a low margin distributor, which seems to be trading OK. 4% dividend yield appeals.

De La Rue (LON:DLAR) - good news on reduced pension scheme funding requirements. This should boost the share price.

Unbound (LON:UBG) - results to 31 Jan 2022 are the closing figures for Electra Private Equity, so are of little relevance to the new version of this company. However, the commentary provides a lot of background information on the new strategy for Unbound. 

Dotdigital (LON:DOTD) - shares plunge further, on wobbly outlook comments accompanying interim results. Very strong balance sheet. I crunch the numbers, and based on earnings growth now having stalled, it's difficult to justify the current price, let alone any upside.

N Brown (LON:BWNG) - down 20% on a not-too-bad update. Although cost pressures mean it expects profits to dip about 18% in FY 2/2023. After the recent collapse of Studio Retail, I now see this business model an uninvestable. There's also a big legal case, which is not mentioned today.


Explanatory notes -

A quick reminder that we don’t recommend any stocks. We aim to review trading updates & results of the day and offer our opinions on them as possible candidates for further research if they interest you. Our opinions will sometimes turn out to be right, and sometimes wrong, because it's anybody's guess what direction market sentiment will take & nobody can predict the future with certainty. We are analysing the company fundamentals, not trying to predict market sentiment.

We stick to companies that have issued news on the day, with market caps up to about £700m. We avoid the smallest, and most speculative companies, and also avoid a few specialist sectors (e.g. natural resources, pharma/biotech).

A key assumption is that readers DYOR (do your own research), and make your own investment decisions. Reader comments are welcomed - please be civil, rational,…

Unlock the rest of this article with a 14 day trial

Already have an account?
Login here